Juvenile idiopathic arthritis (JIA) and pediatric joint disorders
Daniel Horton, MD, MS (he/him/his)
Rutgers Robert Wood Johnson Medical School
New Brunswick, NJ, United States
Disclosure(s): Childhood Arthritis and Rheumatology Research Alliance: Advisor or Review Panel Member (Ongoing), Grant/Research Support (Ongoing), Salary support for serving as JIA Committee Vice Chair and Steering Committee Member (Ongoing); Danisco USA Inc.: Grant/Research Support (Terminated, December 31, 2022)
Daniel Lovell, MD, MPH
Cincinnati Children's Hospital Medical Center
Cincinnati, OH, United States
Disclosure(s): Abbott: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); AbbVie: Consultant (Ongoing); Amgen: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Ongoing); Canadian Arthritis Society: Advisor or Review Panel Member (Ongoing); Celgene: Consultant (Ongoing); Forest Research: Advisor or Review Panel Member (Ongoing); GlaxoSmithKlein(GSK): Consultant (Ongoing); Hoffmann-La Roche: Consultant (Ongoing); Janssen: Consultant (Ongoing); NIH-NIAMS: Advisor or Review Panel Member (Ongoing); Novartis: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Pfizer: Consultant (Ongoing); United Bioscience Corporation: Consultant (Ongoing); Wyeth: Consultant (Ongoing)
Petra Hissink Muller, MD, PhD
Leiden University Medical Center
Leiden, Netherlands
Disclosure(s): No financial relationships with ineligible companies to disclose
Yukiko Kimura, MD
Hackensack Meridian School of Medicine
New York, NY, United States
Disclosure(s): No financial relationships with ineligible companies to disclose
Juvenile idiopathic arthritis (JIA) is a heterogeneous group of chronic arthritis with unknown etiology. Treatment aims to achieve disease control and options for therapy include conventional synthetic (cs) and biologic (b) disease modifying antirheumatic drugs (DMARDs). It is unclear the best initial approach to JIA treatment, and variations exit in initial therapy among providers with some choosing aggressive initial therapy combining csDMARD and bDMARD versus others choosing to step up gradually with therapy if active disease persists. Two speakers will debate data and discuss benefits for early combination versus step-up treatment strategies for JIA.
Moderator: Daniel Horton, MD, MS (he/him/his) – Rutgers Robert Wood Johnson Medical School
Moderator: Daniel Lovell, MD, MPH – Cincinnati Children's Hospital Medical Center
Speaker: Petra Hissink Muller, MD, PhD – Leiden University Medical Center
Speaker: Yukiko Kimura, MD – Hackensack Meridian School of Medicine
Speaker: Petra Hissink Muller, MD, PhD – Leiden University Medical Center
Speaker: Yukiko Kimura, MD – Hackensack Meridian School of Medicine
